NASDAQ$TWST
Twist Bioscience Corporation · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Twist Bioscience's revenue and orders reached record levels amidst the global pandemic. The company's core synthetic biology and next-generation sequencing (NGS) product lines were the primary drivers of success.
Twist Bioscience reported strong fourth-quarter and full-year fiscal 2020 financial results, with a significant increase in revenue and orders compared to the previous year. The company's synthetic biology and NGS product lines drove the overarching success.
- Total revenues were $32.4 million for the fourth quarter of fiscal 2020, compared to $15.7 million for the same period of fiscal 2019.
- Total orders received for the fourth quarter of fiscal 2020 were $42.7 million, compared to $20.0 million for the same period of fiscal 2019.
- Net loss for the fourth quarter of fiscal 2020 was $24.3 million, or $0.54 per share, compared to $31.2 million, or $0.96 per share, for the fourth quarter of fiscal 2019.
- Shipped products to approximately 2,200 customers in fiscal 2020, versus approximately 1,300 in fiscal 2019.
Headline financials
Revenue & EPS history
Twist Bioscience · Revenue · Quarterly
$32.4M
Revenue by segment
Twist Bioscience · $218M total across 2 segments · Q3 2023
- NGS Applications$120M+23.7%55.0%
- DNA Synthesis & Protein$98M+22.5%45.0%
Forward guidance
Twist Bioscience provided financial guidance for the full fiscal year 2021, expecting revenue in the range of $110 million to $118 million.
Tailwinds
- Revenue expected in the range of $110 million to $118 million
- Revenue from Ginkgo Bioworks expected to be approximately $11 to $12 million
- Synbio revenue excluding Ginkgo Bioworks is expected to be in the range of $41 to $44 million
- NGS revenue is estimated to be in the range of $54 to $58 million
- Biopharma revenue is estimated to be approximately $4 million
Headwinds
- Gross margin is expected to be approximately 32% for fiscal 2021
- Operating expenses including R&D and SG&A are expected to be $174 million for the year
- Net loss expected in the range of $136 million to $141 million to reflect our increased investments in our commercial organization and research and development activities
- R&D is expected to be approximately $60 million
- Capital expenditures are expected to be $30 million, including expansion into “Factory of the Future”
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+0.1%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+0.8%
Avg return
30 days after
47%
14 / 30 earnings
Positive
+29.7%
Q4 2023
Best reaction
-23.2%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -7.3% | -5.9% | +19.6% | |
| Q1 2026 | +13.8% | -5.9% | -10.2% | |
| Q4 2025 | -10.0% | -14.9% | +3.4% | |
| Q2 2025 | -8.5% | -16.9% | -20.8% | |
| Q1 2025 | +0.7% | -0.1% | -19.7% | |
| Q4 2024 | +12.0% | +14.5% | +20.9% | |
| Q3 2024 | -14.6% | -16.0% | -18.5% | |
| Q2 2024 | +28.9% | +34.9% | +31.1% | |
| Q1 2024 | +9.5% | +5.1% | +16.9% | |
| Q4 2023 | +29.7% | +24.9% | +81.5% | |
| Q3 2023 | +14.9% | +9.3% | +14.0% | |
| Q2 2023 | +3.6% | +2.1% | +26.0% | |
| Q1 2023 | -23.2% | -15.2% | -37.1% | |
| Q4 2022 | +0.8% | +0.5% | -0.6% | |
| Q3 2022 | +20.8% | +12.4% | -17.2% | |
| Q2 2022 | -9.9% | -16.3% | -12.6% | |
| Q1 2022 | -1.0% | +6.0% | -21.0% | |
| Q4 2021 | -12.6% | -14.1% | -22.4% | |
| Q3 2021 | -9.1% | -15.8% | -7.6% | |
| Q2 2021 | +6.2% | -9.4% | -12.4% | |
| Q1 2021 | -16.8% | -5.5% | -38.1% | |
| Q4 2020 | -9.9% | -0.8% | +44.3% | |
| Q3 2020 | -7.2% | -16.3% | -4.8% | |
| Q2 2020 | +5.1% | +4.6% | +0.7% | |
| Q1 2020 | +21.3% | +14.0% | +31.4% | |
| Q4 2019 | +4.6% | +5.8% | -15.5% | |
| Q3 2019 | -11.2% | -11.8% | -13.9% | |
| Q2 2019 | -9.9% | -9.7% | -3.9% | |
| Q1 2019 | -9.2% | -11.8% | -6.9% | |
| Q4 2018 | -9.2% | -9.4% | +18.6% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro